Our shares are listed for trading on the Nasdaq under the symbol “INCR” and on the TASE under the symbol “INCR”. Our principal executive offices are located at 85 Medinat ha Yehudim Street, 4676670 Israel. Our telephone number in Israel is +972 77 460 5012.
Partnerships Product sourcing/partnerships with Tilray, Organigram, and Charlotte's Web; equity investee Cannassol Ltd. (cannabis R&D)
Status note 20-F describes the business as producing/distributing 'pharmaceutical-grade cannabis and cannabis-based products' and medical cannabis (Canndoc subsidiary, EU-GMP standards).
Per-asset detail extracted from the 20-F filed 2026-04-30. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.